Home
HelpTest Code CRMWC Collapsin Response-Mediator Protein-5-IgG, Western Blot, Spinal Fluid
Useful For
Evaluation of cases of chorea, vision loss, cranial neuropathy and myelopathy
Method Name
Western Blot
Reporting Name
CRMP-5-IgG Western Blot, CSFSpecimen Type
CSFOrdering Guidance
It is recommended an evaluation be ordered in conjunction with this testing if not previously performed. Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, see Autoimmune Neurology Test Ordering Guide.
Additional Testing Requirements
Shipping Instructions
Send specimen refrigerated.
Necessary Information
Provide the following information:
-Relevant clinical information
-Ordering healthcare professional name, phone number, mailing address, and e-mail address
Specimen Required
Container/Tube: Sterile vial
Specimen Volume: 3 mL
Specimen Minimum Volume
2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| CSF | Refrigerated (preferred) | 28 days |
| Frozen | 28 days | |
| Ambient | 72 hours |
Reference Values
Negative
Interpretation
A positive result confirms that a patient's subacute neurological disorder has an autoimmune basis and is likely to be associated with a small-cell lung carcinoma (SCLC) or thymoma, which may be occult.(1,2) A positive result has a predictive value of 90% for neoplasm (77% SCLC, 6% thymoma).(1) Seropositivity is found in approximately 3% of patients who have SCLC with limited metastasis without evidence of neurological autoimmunity.(6)
Clinical-serological correlations have not yet been established for children.
Western blot analysis is indicated when interfering nonorgan-specific or coexisting neuron-specific autoantibodies in serum or spinal fluid preclude unambiguous detection of CRMP-5-IgG by indirect immunofluorescence assay, or when the immunofluorescence assay is negative in a patient whose neurological presentation suggests a CRMP-5-IgG-related syndrome.
Clinical Reference
1. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146-154
2. Vernino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol. 2002;51(5):625-630
3. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res. 2004;10(21):7270-7275
4. Galanis E, Frytak S, Rowland KM Jr, et al. Neuronal autoantibody titers in the course of small cell lung carcinoma and platinum associated neuropathy. Cancer Immunol Immunother 1999;48(2-3):85-90
5. Klein CJ. Autoimmune-mediated peripheral neuropathies and autoimmune pain. In: Pittock SJ, Vincent A, eds. Handbook of Clinical Neurology; Autoimmune Neurology. Elsevier; 2016 pp 417-446
Day(s) Performed
Monday through Thursday
Report Available
5 to 10 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
84182
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CRMWC | CRMP-5-IgG Western Blot, CSF | 53707-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 21747 | CRMP-5-IgG Western Blot, CSF | 53707-6 |